ClinicaliQ Trial Snapshot
- Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity — Recruiting • Phase III • Diabetes / Metabolic • NCT07311850.
- MET097 injected once weekly helped adults with obesity or overweight lose weight over 64 weeks of treatment.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks. Conditions: Obesity and Overweight Interventions: MET097, Placebo Lead Sponsor: Pfizer Planned Enrollment: 3501 participants